MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

Erratum for Eaton et al., Mol Pharmacol 64 (6) 1283-1294.
0026-895X/04/6601-197-$20.00
Mol Pharmacol 66:197-, 2004

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content

Correction to "Characterization of human {alpha}4{beta}2-nicotinic acetylcholine receptors stably and heterologously expressed in native nicotinic receptor-null SH-EP1 human epithelial cells"

In the above article [Eaton JB, Peng J-H, Schroeder KM, George AA, Fryer JD, Krishnan C, Buhlman L, Kuo Y-P, Steinlein O, and Lukas RJ (2003) Mol Pharmacol 64:1283-1294], Table 3 was incorrect due to printing errors. The corrected table appears below.Go


View this table:
[in this window]
[in a new window]
  		TABLE 3 Parameters for interactions of indicated drugs with h{alpha}4{beta}2-nAChR in transfected SH-EP1 cells

Results presented in Figs. 6 to 9 and in Tables 1 and 2 are summarized. Functional EC50 values for agonists (column 2), functional IC50 values for antagonists (column 3; functional IC50 values given in parentheses for nicotine and suberyldicholine from fits to the self-inhibitory phase of agonist dose-response profiles for those drugs), and [3H]EBDN binding competition Ki values (column 4), all in micromolar, are expressed to allow comparisons between functional and radioligand binding competition affinities for the indicated ligands (drug; column 1). Also indicated (F/B; column 5) is the ratio between the functional EC50/IC50 and the binding competition Ki value (based on the IC50 value but corrected for the concentration of H-EBDN used in those assays and for the H-EBDN binding KD of 10 pM using the Cheng-Prusoff correction) for each ligand. The notations following the drug name for selected ligands indicate, from results shown in Fig. 9, functional antagonism actions as a noncompetitive inhibitor (N), a competitive inhibitor (C), or a mixed competitive/noncompetitive inhibitor (N/C).

 

We regret this error and apologize for any confusion or inconvenience it may have caused.





This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics